These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34333045)

  • 21. Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.
    Fisser MC; Rommer A; Steinleitner K; Heller G; Herbst F; Wiese M; Glimm H; Sill H; Wieser R
    Mol Carcinog; 2015 Dec; 54(12):1815-9. PubMed ID: 25491945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCOR regulates myeloid cell proliferation and differentiation.
    Cao Q; Gearhart MD; Gery S; Shojaee S; Yang H; Sun H; Lin DC; Bai JW; Mead M; Zhao Z; Chen Q; Chien WW; Alkan S; Alpermann T; Haferlach T; Müschen M; Bardwell VJ; Koeffler HP
    Leukemia; 2016 May; 30(5):1155-65. PubMed ID: 26847029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy.
    Maganti HB; Jrade H; Cafariello C; Manias Rothberg JL; Porter CJ; Yockell-Lelièvre J; Battaion HL; Khan ST; Howard JP; Li Y; Grzybowski AT; Sabri E; Ruthenburg AJ; Dilworth FJ; Perkins TJ; Sabloff M; Ito CY; Stanford WL
    Cancer Discov; 2018 Nov; 8(11):1376-1389. PubMed ID: 30115703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
    Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
    Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
    Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia.
    Churpek JE; Pyrtel K; Kanchi KL; Shao J; Koboldt D; Miller CA; Shen D; Fulton R; O'Laughlin M; Fronick C; Pusic I; Uy GL; Braunstein EM; Levis M; Ross J; Elliott K; Heath S; Jiang A; Westervelt P; DiPersio JF; Link DC; Walter MJ; Welch J; Wilson R; Ley TJ; Godley LA; Graubert TA
    Blood; 2015 Nov; 126(22):2484-90. PubMed ID: 26492932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exome sequencing identifies recurrent
    Jallades L; Baseggio L; Sujobert P; Huet S; Chabane K; Callet-Bauchu E; Verney A; Hayette S; Desvignes JP; Salgado D; Levy N; Béroud C; Felman P; Berger F; Magaud JP; Genestier L; Salles G; Traverse-Glehen A
    Haematologica; 2017 Oct; 102(10):1758-1766. PubMed ID: 28751561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.
    Simonetti G; Padella A; do Valle IF; Fontana MC; Fonzi E; Bruno S; Baldazzi C; Guadagnuolo V; Manfrini M; Ferrari A; Paolini S; Papayannidis C; Marconi G; Franchini E; Zuffa E; Laginestra MA; Zanotti F; Astolfi A; Iacobucci I; Bernardi S; Sazzini M; Ficarra E; Hernandez JM; Vandenberghe P; Cools J; Bullinger L; Ottaviani E; Testoni N; Cavo M; Haferlach T; Castellani G; Remondini D; Martinelli G
    Cancer; 2019 Mar; 125(5):712-725. PubMed ID: 30480765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
    Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
    PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML.
    Kempf JM; Weser S; Bartoschek MD; Metzeler KH; Vick B; Herold T; Völse K; Mattes R; Scholz M; Wange LE; Festini M; Ugur E; Roas M; Weigert O; Bultmann S; Leonhardt H; Schotta G; Hiddemann W; Jeremias I; Spiekermann K
    Sci Rep; 2021 Mar; 11(1):5838. PubMed ID: 33712646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
    Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
    J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor.
    Pettirossi V; Venanzi A; Spanhol-Rosseto A; Schiavoni G; Santi A; Tasselli L; Naccari M; Pensato V; Pucciarini A; Martelli MP; Drexler H; Falini B; Tiacci E
    Leukemia; 2023 Feb; 37(2):473-477. PubMed ID: 36635390
    [No Abstract]   [Full Text] [Related]  

  • 33. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOXM1 contributes to treatment failure in acute myeloid leukemia.
    Khan I; Halasi M; Patel A; Schultz R; Kalakota N; Chen YH; Aardsma N; Liu L; Crispino JD; Mahmud N; Frankfurt O; Gartel AL
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia.
    Tiacci E; Grossmann V; Martelli MP; Kohlmann A; Haferlach T; Falini B
    Haematologica; 2012 Jan; 97(1):3-5. PubMed ID: 22210327
    [No Abstract]   [Full Text] [Related]  

  • 36. A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations.
    Li X; Xu F; Wu LY; Zhao YS; Guo J; He Q; Zhang Z; Chang CK; Wu D
    Sci Rep; 2020 Jan; 10(1):826. PubMed ID: 31964915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.
    Zhang H; Savage S; Schultz AR; Bottomly D; White L; Segerdell E; Wilmot B; McWeeney SK; Eide CA; Nechiporuk T; Carlos A; Henson R; Lin C; Searles R; Ho H; Lam YL; Sweat R; Follit C; Jain V; Lind E; Borthakur G; Garcia-Manero G; Ravandi F; Kantarjian HM; Cortes J; Collins R; Buelow DR; Baker SD; Druker BJ; Tyner JW
    Nat Commun; 2019 Jan; 10(1):244. PubMed ID: 30651561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular pathogenesis of AML: translating insights to the clinic.
    Levine RL
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):245-8. PubMed ID: 24309525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
    Ali D; Jönsson-Videsäter K; Deneberg S; Bengtzén S; Nahi H; Paul C; Lehmann S
    Eur J Haematol; 2011 Mar; 86(3):206-15. PubMed ID: 21114538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.